Large meta-analysis sheds new light on how SGLT2 inhibitors affect blood and iron parameters
Research led by internist-nephrologist Dr. Michele Eisenga shows that SGLT2 inhibitors, a class of drugs widely used to treat type 2 diabetes, heart failure and chronic kidney disease, consistently increase hemoglobin and hematocrit levels.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.